A Phase I trial of Regeneron‘s anti-DLL4 antibody Enoticumab in patients with solid tumors showed some evidence of disease stabilization in a subset of patients but also resulted in cardiotoxicity and hypertension [146], which may reflect the role of DLL4/Notch in the vascular endothelium. This evidence concerns the gene DLL4 and hypertensive disorder.